Get the latest news and updates
Nataša Jovic has over twenty years of therapeutic and diagnostic commercialization experience. Nataša is responsible for the commercialization efforts of Microbiome Insights’ novel microbiome-based test for IBD, utilizing a proprietary algorithm based on machine-learning to monitor the gut microbiome over time. Prior to joining Microbiome Insights, Nataša helped launch the first at-home monitoring platform in Ophthalmology for Age-related Macular Degeneration (AMD) and was responsible for the U.S. marketing efforts for Visudyne(R), the first pharmacotherapy for wet AMD. Nataša holds a Bachelor of Science degree from the University of British Columbia and a M.B.A. from the Segal Graduate School of Business at Simon Fraser University.
A Microbiome-Based Test For Inflammatory Bowel Disease
The microbiome plays a role in the pathogenesis of Inflammatory Bowel Disease (IBD). Clinical utility of a microbiome-based test for IBD will be determined by its correlation to clinical endpoints and its effectiveness for monitoring disease. Microbiome Insights is developing a novel microbiome-based test to monitor disease activity in IBD.